Alectinib in ALK-Rearranged NSCLC Patients Following Crizotinib. Final Results and Biological Outcomes - Phase II ATALK Study

被引：0
|
作者：
Cortot, A. [1 ]
Escande, F. [1 ]
Gervais, R. [2 ]
Greillier, L. [3 ]
Corre, R. [4 ]
Veillon, R. [5 ]
Ionescu, M. [6 ]
Felicio, H. [6 ]
Pau, D. [6 ]
Gregoire, V. [1 ]
Girard, N. [7 ]
机构：
[1] Univ Lille, CHU Lille, Inst Pasteur Lille, Cnrs,Inserm,Umr9020,Umr S 1277,Canther, Lille, France
[2] Ctr Francois Baclesse, Caen, France
[3] Aix Marseille Univ, Marseille, France
[4] Ch Cornouaille, Quimper, France
[5] CHU Bordeaux, Serv Malad Resp, Bordeaux, France
[6] Labs Roche, Boulogne, France
[7] Inst Curie, Paris, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
non-small cell lung cancer; ALK; Alectinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P84.06
引用
收藏
页码：S658 / S658
页数：1
相关论文
共 50 条
  • [1] ALECTINIB IS ACTIVE IN CRIZOTINIB-RESISTANT ALK-REARRANGED NSCLC
    Gadgeel, S. M.
    Gandhi, L.
    Riely, G. J.
    Chiappori, A. A.
    West, H. L.
    Azada, M. C.
    CANCER DISCOVERY, 2014, 4 (10) : 1113 - 1113
  • [2] Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib
    Ji, Jingran
    Mitra, Anupam
    Camidge, D. Ross
    Riess, Jonathan W.
    CLINICAL LUNG CANCER, 2021, 22 (06) : E851 - E855
  • [3] Complete Response to Alectinib Following Crizotinib in an ALK-Rearranged Metastatic Inflammatory Myofibroblastic Tumor
    Xavier, C.
    Canedo, F.
    Lima, F.
    Melo, R.
    Lima, L. G.
    Marin, J. F.
    Souza, C.
    Feher, O.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S661 - S662
  • [4] Updates on PFS and safety results of a Phase I/II study (AF-001JP) of alectinib in ALK-rearranged advanced NSCLC
    Kozuki, Toshiyuki
    Nishio, Makoto
    Kiura, Katsuyuki
    Seto, Takashi
    Nakagawa, Kazuhiko
    Maemondo, Makoto
    Inoue, Akira
    Hida, Toyoaki
    Tanaka, Tomohiro
    Tamura, Tomohide
    ANNALS OF ONCOLOGY, 2015, 26 : 73 - 73
  • [5] Treatment with Alectinib after Crizotinib-Induced Hepatitis in an ALK-Rearranged Advanced NSCLC-Patient
    Duarte, F.
    Rodrigues, L.
    Paes, F.
    Diniz, P.
    De Almada, H.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S667 - S667
  • [6] Sustained Response to Crizotinib After Resistance to First-Line Alectinib Treatment in Two Patients With ALK-Rearranged NSCLC
    Zheng, Jing
    Sun, Wenjia
    Chen, Wenhong
    Zhou, Jianying
    Zhou, Jianya
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (09) : E150 - E153
  • [7] Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study
    Ou, Sai-Hong Ignatius
    Ahn, Jin Seok
    De Petris, Luigi
    Govindan, Ramaswamy
    Yang, James Chih-Hsin
    Hughes, Brett
    Lena, Herve
    Moro-Sibilot, Denis
    Bearz, Alessandra
    Ramirez, Santiago Viteri
    Mekhail, Tarek
    Spira, Alexander
    Bordogna, Walter
    Balas, Bogdana
    Morcos, Peter N.
    Monnet, Annabelle
    Zeaiter, Ali
    Kim, Dong-Wan
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (07) : 661 - +
  • [8] BUDGET IMPACT ANALYSIS OF ALECTINIB FOR THE TREATMENT OF PATIENTS WITH UNTREATED ALK-REARRANGED NSCLC IN ITALY
    Bellone, M.
    Pradelli, L.
    Recchia, A.
    Caputo, A.
    Masetti, L.
    VALUE IN HEALTH, 2018, 21 : S28 - S28
  • [9] ctDNA NGS for Guiding Crizotinib Treatment in ALK-Rearranged Advanced NSCLC Patients (Pts)
    He, Y.
    Zhao, J.
    Liu, C.
    Chen, R.
    Xia, X.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S573 - S573
  • [10] Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib
    Takeyasu, Yuki
    Yoshida, Tatsuya
    Masuda, Ken
    Matsumoto, Yuji
    Shinno, Yuki
    Okuma, Yusuke
    Goto, Yasushi
    Horinouchi, Hidehito
    Yamamoto, Noboru
    Ohe, Yuichiro
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (05):
12345